Experiment Protocol Biomedical Engineer in Thailand Bangkok –Free Word Template Download with AI

This Experiment Protocol outlines the rigorous procedures required for the clinical validation of a novel non-invasive hemodynamic monitoring device. The study is conducted under the supervision of a certified Biomedical Engineer within the healthcare infrastructure of Thailand Bangkok. As a leading hub for medical tourism and advanced healthcare in Southeast Asia, Thailand Bangkok offers a unique demographic and clinical environment for testing biomedical innovations.

The primary objective is to evaluate the accuracy, reliability, and safety of the device in a real-world clinical setting, adhering strictly to the regulations set forth by the Thai Food and Drug Administration (Thai FDA) and the Ministry of Public Health. The Biomedical Engineer is responsible for ensuring that the technical specifications of the device align with clinical requirements and that all data collection methods meet international standards for biomedical research.

2.1 Primary Objective

To determine the correlation between the readings provided by the novel hemodynamic monitoring device and the gold-standard invasive arterial line measurements in adult patients undergoing surgery in hospitals located in Thailand Bangkok.

2.2 Secondary Objectives

• To assess the usability and ergonomic design of the device from the perspective of nursing staff and physicians.
• To evaluate the device's performance under varying environmental conditions typical of Thailand Bangkok, including high humidity and temperature fluctuations.
• To identify any adverse events related to the device usage during the trial period.

3.1 Study Design

This is a prospective, single-center, observational study. The Biomedical Engineer will oversee the technical setup and calibration of all equipment prior to patient enrollment. The study will be conducted in collaboration with a major tertiary care hospital in Thailand Bangkok, ensuring access to a diverse patient population.

3.2 Participants

Inclusion Criteria:

• Adults aged 18-75 years.
• Scheduled for elective surgery requiring general anesthesia.
• Written informed consent obtained in accordance with Thai ethical standards.

• Patients with severe peripheral vascular disease.
• Patients with skin conditions at the sensor application site.
• Pregnant women.

3.3 Procedures

Upon admission to the operating room, the Biomedical Engineer will calibrate the novel device and the reference invasive arterial line. Data will be collected continuously throughout the surgical procedure. The Biomedical Engineer will monitor the data acquisition system to ensure integrity and troubleshoot any technical issues immediately.

This Experiment Protocol has been reviewed and approved by the Institutional Review Board (IRB) of the participating hospital in Thailand Bangkok. The study adheres to the Declaration of Helsinki and the Good Clinical Practice (GCP) guidelines mandated by the Thai FDA.

Patient confidentiality is paramount. All data will be anonymized and stored on secure servers located within Thailand Bangkok, compliant with the Personal Data Protection Act (PDPA) of Thailand. The Biomedical Engineer is trained in ethical data handling and will ensure that no personally identifiable information is included in the technical datasets.

Data will be collected using a dedicated software platform designed by the Biomedical Engineer. Statistical analysis will be performed using Bland-Altman plots to assess agreement between the novel device and the reference standard. The Biomedical Engineer will collaborate with biostatisticians to interpret the results and determine clinical significance.

Any deviations from the protocol must be documented and reported to the IRB. The Biomedical Engineer is responsible for maintaining a detailed log of all technical parameters, calibration records, and device performance metrics.

The Biomedical Engineer will conduct a risk assessment prior to the initiation of the study. Potential risks include skin irritation from sensor adhesion and minor discomfort from the invasive reference line. A Data Safety Monitoring Board (DSMB) will review safety data at regular intervals.

In the event of a serious adverse event, the Biomedical Engineer will immediately halt data collection for the affected patient and notify the principal investigator and the hospital's medical team. The device will be removed, and appropriate medical care will be provided.

This Experiment Protocol provides a comprehensive framework for the clinical validation of the novel hemodynamic monitoring device. By leveraging the expertise of a Biomedical Engineer and the advanced healthcare facilities in Thailand Bangkok, this study aims to contribute valuable data to the field of biomedical engineering and improve patient care outcomes.